ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Gynecologic Cancers

ASCO 2016 Genitourinary Cancers Symposium

Cancer Network presents exclusive coverage from the American Society of Clinical Oncology (ASCO) 2016 Genitourinary Cancers Symposium, held January 7–9 in San Francisco. We’ll bring you reports as we cover the latest research, trials, scientific advances, and controversies that are changing the way genitourinary cancers are managed and treated.

Gynecologic Cancers

In this review, we will summarize clinical trials that have used various immunotherapeutic strategies, with a particular focus on recently emerging data for new agents and combinations.

The advent of immunotherapy presents us with new treatment approaches in gynecologic cancers, with preliminarily promising outcomes. Multiple clinical trials are currently being conducted to better define the role of immunotherapy. Further investigation is warranted to develop and identify predictive biomarkers.

Adolescent girls who live in predominantly Hispanic and high poverty communities are more likely to have had at least one HPV vaccine dose compared to girls in low poverty communities and those with different ethnic make up.

A mouse study found that resveratrol has a significant antitumor effect in an ovarian cancer model, and also suppressed tumor regrowth following cisplatin.

Women older than 70 received less treatment for ovarian cancer than did their younger counterparts, according to the results of a single-center French study.

Women with chemotherapy-naive advanced ovarian cancer gained significant delays in the progression of their disease when adding nintedanib to carboplatin/paclitaxel.

In this interview we discuss sexual health during cancer treatment and some of the disappointments of precision medicine.

Pages

Subscribe to Gynecologic Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.